The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020

Background: In recent years, new drug development on lung cancer is in full swing in China. The aim of this study was to overview the changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. Methods: We analysed anti-lung cancer drug clinical trials registered on three websites including the China National Medical Products Administration Centre for Drug Evaluation platform, the Chinese Clinical Trial Registry and ClinicalTrials.gov. Findings: A total of 1595 anti-lung cancer drug clinical trials from Jan 1st, 2005 to Dec 31st, 2020 were extracted, which included 630 (39.5%) investigator-initiated trials (IITs), 698 (43.8%) domestic industry-sponsored trials (ISTs), and 267 (16.7%) international ISTs. During the past 16 years, the number of anti-lung cancer clinical trials including IITs and domestic ISTs had a remarkable growth, however, the number of international ISTs increased slowly. The number of principal clinical trial units also increased significantly over time. Of the 1595 trials, the largest growth was observed in phase I trials during 2013-2020, with an average annual growth rate of 38.6%. 278 trials were led by principal investigators (PI) from Guangdong, followed by Beijing (n = 273) and Shanghai (n = 257). Among the 965 ISTs, clinical trials involving targeted drugs (588, 60.9%) accounted for the largest proportion, followed by immunotherapeutic drugs (284, 29.4%), cytotoxic drugs (75, 7.8%), and traditional Chinese medicine (18, 1.9%). In terms of targeted drugs, EGFR-TKIs remained the most studied drugs (225/588, 38.27%). As for immunotherapy, 125 out of 284 (44.01%) trials involved PD-1 inhibitors, 60 (21 .13%) trials involved PD-L1 inhibitors, and seven (2.46%) trials involved CTLA-4 inhibitors. Interpretation: In the past 16 years, the development of anti-lung cancer drug clinical trials has achieved much progress in mainland China. The most progress lied in targeted therapy and immunotherapy. (C) 2021 The Author(s). Published by Elsevier Ltd.

Automated summary

In mainland China, significant progress has been made in anti-lung cancer drug clinical trials over the past 16 years, with the most notable advancements seen in targeted therapy and immunotherapy.